<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252720</url>
  </required_header>
  <id_info>
    <org_study_id>D2453C00046</org_study_id>
    <secondary_id>DIRECT</secondary_id>
    <secondary_id>SH-AHM-0046</secondary_id>
    <nct_id>NCT00252720</nct_id>
  </id_info>
  <brief_title>DIabetic Retinopathy Candesartan Trials.</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether candesartan, compared to placebo reduces the
      progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic
      patients with retinopathy.

      The secondary objective is to determine whether candesartan, compared to placebo, reduces the
      incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic
      retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion
      rate (UAER).

      This study is part of the DIRECT Programme also including a primary prevention study of
      diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes.
      The primary objective for all three pooled studies is to determine whether candesartan,
      compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale</measure>
    <time_frame>From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.</time_frame>
    <description>Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Regression of Diabetic Retinopathy.</measure>
    <time_frame>From baseline to the end of the study, i.e., 5 years</time_frame>
    <description>Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).</measure>
    <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
    <description>Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Urinary Albumin Excretion Rate (UAER).</measure>
    <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
    <description>An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1850</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>candesartan cilexetil 32 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan</intervention_name>
    <description>32 mg oral tablet</description>
    <arm_group_label>candesartan</arm_group_label>
    <other_name>ATACAND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 - 55 years with type 1 diabetes diagnosed before age of 36
             years and in need for continuous insulin treatment within 1 year of diagnosis of
             diabetes are included.

          -  Duration of diabetes for &gt; 1 year and &lt; 20 years with stable diabetic therapy within
             last 6 months.

          -  Patients with untreated resting mean sitting SBP &lt; 130 mmHg, mean sitting DBP &lt; 85
             mmHg and with retinal photograph grading level &gt; 20/10 up to &lt; 47/47 (on ETDRS
             severity scale).

        Exclusion Criteria:

          -  Patients with the following conditions are excluded from participation on the study:

          -  Cataract or media opacity of a degree which precludes taking gradable retinal
             photographs

          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil

          -  History or presence of proliferative retinopathy

          -  History or presence of clinical significant macular oedema (CSME)

          -  History or evidence of photocoagulation of the retina

          -  Other retinal conditions which may mask assessment, eg, retinal vein occlusion

          -  Positive micral dipstick test

          -  Presence of secondary diabetes

          -  Pregnant or lactating women or women of child bearing potential not practicing an
             adequate method of contraception

          -  Need of treatment with ACE-inhibitor

          -  Haemodynamically significant aortic or mitral valve stenosis

          -  Known renal artery stenosis or kidney transplantation

          -  Hypersensitivity to study drug

          -  Severe concomitant disease which may interfere with the assessment of the patient, eg,
             malignancy, as judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Atacand Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1268&amp;filename=CSR-D2453C00046.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1268&amp;filename=CSR-D2453C00046.pdf</url>
    <description>CSR-D2453C00046.pdf</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>March 19, 2012</results_first_submitted>
  <results_first_submitted_qc>May 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2014</results_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled in the DIRECT programme 8 June 2001 and last subject completed the DIRECT programme 16 April 2008 mainly in hospital based clinics. The study investigators enrolled 4514 patients with type 1 diabetes to either Study 45 or 46, of whom 1905 proceeded to randomization into Study 46 (1421 into Study 45).</recruitment_details>
      <pre_assignment_details>The most common reason for not being randomized was that all eligibility criteria were not fulfilled, followed by withdrawn informed consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="951"/>
                <participants group_id="P2" count="954"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="819"/>
                <participants group_id="P2" count="789"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moving</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mainly patients lost to follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="951"/>
            <count group_id="B2" value="954"/>
            <count group_id="B3" value="1905"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="951"/>
                    <measurement group_id="B2" value="954"/>
                    <measurement group_id="B3" value="1905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="8.5"/>
                    <measurement group_id="B2" value="31.9" spread="8.5"/>
                    <measurement group_id="B3" value="31.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="553"/>
                    <measurement group_id="B3" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="619"/>
                    <measurement group_id="B3" value="1214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale</title>
        <description>Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.</description>
        <time_frame>From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.</time_frame>
        <population>The population was the Intention to Treat population which includes all randomized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale</title>
          <description>Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.</description>
          <population>The population was the Intention to Treat population which includes all randomized patients with any post-randomization data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="951"/>
                <count group_id="O2" value="954"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="0.034"/>
                    <measurement group_id="O2" value="124" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8487</p_value>
            <method>Log Rank</method>
            <method_desc>Generalized</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.800</ci_lower_limit>
            <ci_upper_limit>1.312</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Regression of Diabetic Retinopathy.</title>
        <description>Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).</description>
        <time_frame>From baseline to the end of the study, i.e., 5 years</time_frame>
        <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Regression of Diabetic Retinopathy.</title>
          <description>Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).</description>
          <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="951"/>
                <count group_id="O2" value="954"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="0.039"/>
                    <measurement group_id="O2" value="139" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).</title>
        <description>Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.</description>
        <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
        <population>The population was the Intention To Treat population whick includes all randomized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).</title>
          <description>Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.</description>
          <population>The population was the Intention To Treat population whick includes all randomized patients with any post-randomization data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="951"/>
                <count group_id="O2" value="954"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="0.03"/>
                    <measurement group_id="O2" value="107" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Urinary Albumin Excretion Rate (UAER).</title>
        <description>An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient</description>
        <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
        <population>The population was the Intention To Treat population which includes all randimized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Urinary Albumin Excretion Rate (UAER).</title>
          <description>An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient</description>
          <population>The population was the Intention To Treat population which includes all randimized patients with any post-randomization data.</population>
          <units>log (µg/min)/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="951"/>
                <count group_id="O2" value="954"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.569" lower_limit="0.489" upper_limit="0.648"/>
                    <measurement group_id="O2" value="0.642" lower_limit="0.563" upper_limit="0.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment. During Treatment refers to the period of actual treatment with randomized study drug, ie, is a subset of the patients included in During Study. During Treatment period only includes AEs reported while patients were on study treatment.</time_frame>
      <desc>Population used was the safety population which includes all patients who received at least 1 dose of randomized study strug and for whom any post-dose data were available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Disease Congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepato-Lenticular Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Vestibular Neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Change Of Bowel Habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Coeliac Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gingival Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Rectal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Foreign Body Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Macrosomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Adnexitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Corneal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Encephalitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Infected Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Perianal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Viral Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Viral Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ligament Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cartilage Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Frostbite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Injury Corneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Skull Fractured Base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Sports Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tendon Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tumour Marker Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dupuytren's Contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Osteoarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Trigger Finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroadenoma Of Breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Anaplastic Astrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Benign Colonic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hepatic Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Penile Wart</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Hyperosmolar Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidotic Hyperglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Foetal Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Intra-Uterine Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Polyhydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ureteric Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Tonsillar Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Vocal Cord Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dermal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Erythema Nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="951"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Niklas Berglind, GPS Atacand</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+46 31 7766310</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

